Get the Stockscreener App
2.85
5.17%
0.14
After Hours:
2.80
-0.05
-1.75%
Abcellera Biologics Inc Stock (ABCL) Forecast
The Abcellera Biologics Inc (ABCL) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $21.41, representing a +651.11% increase from the current price of $2.85. The highest analyst price target is $21.64, and the lowest is $21.17.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ABCL Price Target
Average 20.16
(+607.41% Upside)
Is Abcellera Biologics Inc (ABCL) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 50.52 | Neutral |
| STOCH(9,6) | 22.35 | Neutral |
| STOCHRSI(14) | 53.07 | Neutral |
| MACD(12,26) | -0.00531 | Sell |
| ADX(14) | 16.55 | Neutral |
| William %R | -50.54 | Neutral |
| CCI(14) | -54.80 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.854
Sell
|
2.8271
Buy
|
| MA20 |
2.889
Sell
|
2.844
Buy
|
| MA50 |
2.8074
Buy
|
2.8143
Buy
|
| MA100 |
2.7107
Buy
|
2.8856
Sell
|
| MA200 |
3.2318
Sell
|
3.2755
Sell
|
Buy: 5
Sell: 5
Neutral: 0
Summary: Neutral
According to our latest analysis, ABCL could be considered a Neutral, with 17 technical analysis indicators signaling 5 Buy signals, 6 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on ABCL, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 50.52 indicates that ABCL is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 22.35 indicates that ABCL is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 53.07 indicates that ABCL is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 16.55 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -54.8 indicates that ABCL is still oversold but not to an extreme extent.
Long-term ABCL price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Abcellera Biologics Inc financial reports and earnings history, Abcellera Biologics Inc (ABCL) stock could reach $39.18 by 2030, $176.86 by 2040 and $106.76 by 2050. See the projected annual prices until 2050 of the Abcellera Biologics Inc stock below:
- Abcellera Biologics Inc (ABCL) is expected to reach an average price of $30.12 in 2035, with a high prediction of $32.29 and a low estimate of $30.15. This indicates an $956.80% rise from the last recorded price of $2.85.
- Abcellera Biologics Inc (ABCL) stock is projected to chart a bullish course in 2040, with an average price target of $178.76, representing an $6,172% surge from its current level. The forecast ranges from a conservative $178.91 to a sky-high $176.86.
- Our analysts predict Abcellera Biologics Inc (ABCL) to jump 5,613% by 2045, soaring from $164.25 to an average price of $162.83, potentially reaching $164.90. While $164.25 is the low estimate, the potential upside is significant.
- Abcellera Biologics Inc (ABCL) stock is expected to climb by 2050, reaching an average of $102.42, a $3,494% jump from its current level. However, a wide range of estimates exists, with high and low targets of $106.76 and $103.46, respectively, highlighting the market's uncertainty.
Abcellera Biologics Inc Stock (ABCL) Year by Year Forecast
Abcellera Biologics Inc Stock (ABCL) Price Forecast for 2025
Abcellera Biologics Inc Stock (ABCL) is expected to reach an average price of $20.16 in 2025, with a high prediction of $23.36 and a low estimate of $16.96. This indicates an +607.41% rise from the last recorded price of $2.85.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $19.74 | $21.17 | $21.64 | +592.75% |
| February, 2025 | $16.13 | $18.74 | $19.12 | +465.90% |
| March, 2025 | $20.31 | $16.96 | $18.65 | +612.72% |
| April, 2025 | $19.59 | $19.82 | $19.07 | +587.31% |
| May, 2025 | $19.75 | $19.75 | $18.63 | +593.08% |
| June, 2025 | $18.64 | $18.79 | $18.19 | +553.95% |
| July, 2025 | $22.90 | $21.30 | $23.36 | +703.62% |
| August, 2025 | $22.13 | $22.24 | $22.13 | +676.41% |
| September, 2025 | $21.39 | $22.13 | $21.86 | +650.61% |
| October, 2025 | $20.19 | $19.77 | $20.18 | +608.35% |
| November, 2025 | $21.11 | $21.07 | $20.93 | +640.79% |
| December, 2025 | $18.96 | $19.92 | $19.94 | +565.20% |
Abcellera Biologics Inc Stock (ABCL) Price Forecast for 2026
The predicted value for Abcellera Biologics Inc (ABCL) in 2026 is set at an average of $12.45. Estimates vary from a peak of $16.64 to a trough of $8.2692, indicating an +336.99% surge from the present price of $2.85.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $15.80 | $16.00 | $16.64 | +454.56% |
| February, 2026 | $15.59 | $15.75 | $14.99 | +446.93% |
| March, 2026 | $13.53 | $13.86 | $13.76 | +374.81% |
| April, 2026 | $14.55 | $13.68 | $13.23 | +410.45% |
| May, 2026 | $12.60 | $13.07 | $13.43 | +342.19% |
| June, 2026 | $8.4969 | $10.52 | $10.94 | +198.14% |
| July, 2026 | $10.56 | $8.2692 | $8.3126 | +270.62% |
| August, 2026 | $10.69 | $10.80 | $9.966 | +274.99% |
| September, 2026 | $7.9729 | $8.9379 | $9.3383 | +179.75% |
| October, 2026 | $9.9175 | $9.3739 | $9.6875 | +247.98% |
| November, 2026 | $10.14 | $10.22 | $9.9009 | +255.86% |
| December, 2026 | $9.6578 | $9.5866 | $9.5332 | +238.87% |
Abcellera Biologics Inc Stock (ABCL) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Abcellera Biologics Inc (ABCL) is $5.3473, with a high forecast of $9.91 and a low forecast of $0.7845. This indicates an +87.62% increase from the last price of $2.85.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $8.8023 | $9.8473 | $9.91 | +208.85% |
| February, 2027 | $7.1869 | $7.7269 | $8.2435 | +152.17% |
| March, 2027 | $5.8726 | $6.7014 | $7.4203 | +106.06% |
| April, 2027 | $7.1272 | $5.7149 | $6.2272 | +150.08% |
| May, 2027 | $6.4618 | $6.6718 | $6.9283 | +126.73% |
| June, 2027 | $6.5875 | $6.4629 | $6.4075 | +131.14% |
| July, 2027 | $6.0621 | $6.3021 | $6.2511 | +112.70% |
| August, 2027 | $4.9066 | $5.0166 | $5.1832 | +72.16% |
| September, 2027 | $2.6023 | $3.0223 | $4.1028 | -8.69% |
| October, 2027 | $2.2169 | $2.2858 | $2.1035 | -22.21% |
| November, 2027 | $1.5115 | $1.8265 | $1.6281 | -46.97% |
| December, 2027 | $0.8072 | $0.7845 | $0.9526 | -71.68% |
Abcellera Biologics Inc Stock (ABCL) Price Forecast for 2028
In 2028, Abcellera Biologics Inc (ABCL) is projected to reach an average price of $29.91, with a high projection of $59.77 and a low estimate of $0.0425. This indicates an +949.30% rise from the last price of $2.85.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $0.4018 | $0.4938 | $0.3295 | -85.90% |
| February, 2028 | $0.1264 | $0.1814 | $0.217 | -95.57% |
| March, 2028 | $49.55 | $0.0425 | $46.79 | +1,638% |
| April, 2028 | $41.05 | $41.92 | $41.85 | +1,340% |
| May, 2028 | $48.97 | $44.16 | $48.66 | +1,618% |
| June, 2028 | $53.13 | $53.84 | $52.33 | +1,764% |
| July, 2028 | $55.52 | $55.57 | $52.60 | +1,848% |
| August, 2028 | $54.11 | $49.78 | $52.48 | +1,798% |
| September, 2028 | $56.41 | $56.41 | $55.97 | +1,879% |
| October, 2028 | $60.95 | $58.16 | $59.77 | +2,038% |
| November, 2028 | $57.07 | $58.50 | $59.77 | +1,902% |
| December, 2028 | $52.62 | $55.43 | $56.24 | +1,746% |
Abcellera Biologics Inc Stock (ABCL) Price Forecast for 2029
The 2029 price forecast for Abcellera Biologics Inc Stock (ABCL) is $48.42 on average, with a high prediction of $55.46 and a low estimate of $41.38. This represents an +1,599% increase from the previous price of $2.85.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $55.39 | $53.03 | $54.52 | +1,843% |
| February, 2029 | $54.20 | $54.63 | $53.98 | +1,802% |
| March, 2029 | $53.53 | $53.86 | $52.61 | +1,778% |
| April, 2029 | $51.57 | $51.93 | $51.76 | +1,710% |
| May, 2029 | $54.80 | $54.03 | $55.46 | +1,823% |
| June, 2029 | $53.19 | $53.50 | $53.82 | +1,766% |
| July, 2029 | $51.61 | $52.77 | $52.71 | +1,711% |
| August, 2029 | $49.37 | $49.36 | $50.20 | +1,632% |
| September, 2029 | $49.46 | $50.04 | $49.40 | +1,635% |
| October, 2029 | $46.26 | $47.22 | $47.86 | +1,523% |
| November, 2029 | $42.27 | $42.47 | $43.73 | +1,383% |
| December, 2029 | $41.21 | $41.38 | $40.63 | +1,346% |
Abcellera Biologics Inc Stock (ABCL) Price Forecast for 2030
Abcellera Biologics Inc Stock (ABCL) is expected to reach an average price of $30.84 in 2030, with a high forecast of $39.18 and a low forecast of $22.49. This signifies an +982.04% surge from the last price of $2.85.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $38.49 | $38.82 | $39.18 | +1,250% |
| February, 2030 | $38.30 | $37.63 | $37.55 | +1,244% |
| March, 2030 | $35.51 | $35.99 | $36.97 | +1,146% |
| April, 2030 | $30.57 | $32.60 | $33.64 | +972.76% |
| May, 2030 | $31.60 | $29.93 | $29.35 | +1,009% |
| June, 2030 | $30.88 | $31.36 | $30.37 | +983.66% |
| July, 2030 | $27.13 | $28.09 | $29.33 | +851.78% |
| August, 2030 | $28.23 | $28.21 | $28.00 | +890.70% |
| September, 2030 | $27.62 | $27.83 | $27.73 | +869.27% |
| October, 2030 | $26.10 | $26.23 | $26.81 | +815.63% |
| November, 2030 | $24.40 | $25.45 | $25.93 | +756.30% |
| December, 2030 | $21.95 | $22.49 | $23.64 | +670.31% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):